Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer

BackgroundADP-A2M10 specific peptide enhanced affinity receptor (SPEAR) T cells (ADP-A2M10) are genetically engineered autologous T cells that express a high-affinity melanoma-associated antigen A10 (MAGE-A10)-specific T-cell receptor (TCR) targeting MAGE-A10+ tumors in the context of human leukocyt...

Full description

Bibliographic Details
Main Authors:	Bachier, C. (Author), Bai, J. (Author), Batrakou, D. (Author), Blumenschein, G.R (Author), Broad, R. (Author), Devarakonda, S. (Author), Doger de Spéville, B. (Author), Edelman, M.J (Author), Fayngerts, S. (Author), Fracasso, P.M (Author), Frigault, M.J (Author), Gainor, J. (Author), Gerry, A. (Author), Govindan, R. (Author), Heymach, J.V (Author), Holdich, T. (Author), Hyland, N. (Author), Johnson, M. (Author), Lam, V.K (Author), Marks, D. (Author), Moreno, V. (Author), Navenot, J.-M (Author), Norry, E. (Author), Olszanski, A.J (Author), Pentony, M.M (Author), Sanderson, J.P (Author), Wolchinsky, Z. (Author)
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2022
Subjects:	adenocarcinoma adoptive immunotherapy ADP A2M10 adult advanced cancer adverse event aged Aged allele alopecia anemia Antigens, Neoplasm apheresis aplastic anemia Article biopsy cancer staging Carcinoma, Non-Small-Cell Lung CD3+ T lymphocyte CD8+ T lymphocyte cell engineering cell infiltration cell isolation chill clinical article clinical trial clinical trials as topic constipation controlled study cyclophosphamide cytokine release syndrome cytology cytopenia diarrhea drug drug dose escalation drug efficacy drug safety drug tolerability ECOG Performance Status edema erythroderma fatigue female Female fever fludarabine forced expiratory volume forced vital capacity gene expression gene mutation genetic engineering Genetic Engineering graft versus host reaction histology HLA A antigen human Humans hyponatremia hypotension hypoxia immunology Immunotherapy, Adoptive infection leukapheresis leukopenia Lung Neoplasms lung tumor lymphocyte antigen receptor lymphocyte depletion Lymphocyte Depletion lymphocytopenia MAGE-A10 antigen male Male melanoma antigen 10 middle aged Middle Aged multicenter study nausea and vomiting Neoplasm Proteins neurotoxicity neutropenia non small cell lung cancer open study pancytopenia phase 1 clinical trial pneumonia progression free survival rash real time polymerase chain reaction Receptors, Antigen, T-Cell recurrent disease response evaluation criteria in solid tumors specific peptide enhanced affinity receptor t cell squamous cell carcinoma T lymphocyte T lymphocyte receptor tachycardia thrombocytopenia T-Lymphocytes total lung capacity tumor antigen tumor biopsy tumor protein unclassified drug whole exome sequencing
Online Access:	View Fulltext in Publisher

Internet

View Fulltext in Publisher

Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer

Internet

Similar Items